TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
29.14
-0.11 (-0.39%)
As of 10:53AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close29.25
Open28.87
Bid0.00 x 0
Ask0.00 x 0
Day's Range28.87 - 29.21
52 Week Range20.20 - 29.92
Volume2,005
Avg. Volume55,530
Market Cap46.67B
Beta0.41
PE Ratio (TTM)31.12
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.80 (2.73%)
Ex-Dividend Date2017-09-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • We are in recovery mode: Takeda CEO
    CNBC Videos4 months ago

    We are in recovery mode: Takeda CEO

    Christophe Weber, CEO of Takeda Pharmaceutical, talks about how innovation and globalization will help the Japanese company grow in the future.

  • Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth
    Market Realist5 days ago

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    What to Expect from Roche in 2018

  • The Wall Street Journal8 days ago

    [$$] Safety Fears Threaten Global Dengue Vaccine Effort

    Sanofi’s recent disclosure of safety problems with the world’s only approved vaccine against the dengue has complicated efforts to contain a growing global epidemic, public-health experts say.

  • American City Business Journals11 days ago

    Ahead of big J.P. Morgan Healthcare Conference, biotech companies amp up news buzz

    Going into the biggest dealmaking days of the year, biotech companies over the past few weeks have pushed out news about new drugs, new hires, fresh clinical trials and looming IPOs. "The advantage of JPM is everyone's here," said George Scangos, the former Exelixis Inc. (EXEL) and Biogen Inc. (BIIB) CEO who last year took Vir Biotechnology Inc. out of stealth mode days before the conference. With cash flooding into the drug-development industry at a record rate — $10.5 billion last year to biotech and pharmaceutical companies, according to a recent Silicon Valley Bank report — the news flow ahead of this year's conference appears richer and deeper.

  • MarketWatch11 days ago

    Denali stock surges on $150 mln Takeda partnership for up to three neurodegenerative therapies

    Denali Therapeutics Inc. shares surged 3.6% in moderate morning trade Friday on news of the company's $150 million partnership with Takeda Pharmaceutical Co. Ltd. on up to three therapies for neurodegenerative ...

  • Capital Cube20 days ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017
    Capital Cube21 days ago

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Takeda Pharmaceutical Co., Ltd. – Pfizer Inc., Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd. Sponsored ADR and Orexigen Therapeutics, Inc. (PFE-US, MRK-US, RDY-US and OREX-US) that ... Read more (Read more...)

  • Market Realist25 days ago

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

  • Market Realist25 days ago

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

  • Market Realist26 days ago

    Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017

    Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

  • The Fight to Eradicate Dengue Faces Another Setback
    Bloomberg29 days ago

    The Fight to Eradicate Dengue Faces Another Setback

    Break-bone fever is the world’s most pernicious mosquito-borne virus, afflicting as many as 400 million people a year -- making the latest setback in the effort to stop the dengue scourge all the more ...

  • Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run
    InvestorPlacelast month

    Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run

    The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.

  • Reuters2 months ago

    Takeda moves ahead in Zika race with launch of vaccine trial

    Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical trial programme backed by the U.S. government. Its French rival Sanofi had initially been viewed as the large drugmaker best placed to bring the first vaccine to market when Zika erupted as a major public health hazard in Brazil in 2015. Both Takeda and Sanofi have been working on similar vaccines using inactivated or killed whole Zika virus.

  • Market Realist2 months ago

    What Else Could Boost Exelixis’s Future Revenues?

    On October 16, Exelixis and Ipsen announced that Cabometyx (cabozaninib) met its primary endpoint of OS (overall survival) in the phase-3 Celestial trial.

  • Takeda CEO Seeks Deals to Form Identity Beyond Japan Drug Market
    Bloomberg2 months ago

    Takeda CEO Seeks Deals to Form Identity Beyond Japan Drug Market

    Japan’s biggest drugmaker is ready to take on more partnerships and deals -- at the right price -- as it seeks to build an identity beyond the pharmacy shelves of its home market.

  • American City Business Journals2 months ago

    Roivant subsidiary stacks up positive Phase 3 news

    The company announced that Takeda Pharmaceutical Company has reported positive top-line results from a Phase 3 study of relugolix in Japan for the treatment of pain associated with uterine fibroids. The positive results – along with those from another Phase 3 study by Takeda of relugolix announced last month – are slated to be used in support of Myovant’s new drug application for relugolix in the U.S. Myovant is currently advancing relugolix for the treatment of uterine fibroid-caused pain and bleeding as well as prostate cancer.

  • Reuters2 months ago

    Takeda takes on Sanofi with new global dengue vaccine data

    Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia. Japan's top drugmaker has become more international under its French CEO Christophe Weber, who took over in 2015. Sanofi's Dengvaxia is the first-ever approved vaccine for dengue, but it is not perfect and did not protect equally against the four different types of the virus in clinical tests.

  • Capital Cube4 months ago

    ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017
    Capital Cube4 months ago

    Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2018 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Takeda Pharmaceutical Co., Ltd. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Takeda Pharmaceutical Co., Ltd. – Pfizer Inc., Amgen Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Seattle Genetics, Inc., Sanofi Sponsored ADR, Dr. Reddy’s Laboratories Ltd. ... Read more (Read more...)

  • We want to globalize our products and our company, Takeda Pharmaceutical CEO says
    CNBC4 months ago

    We want to globalize our products and our company, Takeda Pharmaceutical CEO says

    Globalization has been key to Takeda Pharmaceutical's strategy to achieving growth, its CEO said.

  • GuruFocus.com5 months ago

    FDA to Review Amgen's Supplement Application for Kyprolis

    Company seeks to add overall survival data

  • Market Realist5 months ago

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.